Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doravirine vs Darunavir/Ritonavir in Treatment-Naïve HIV-1
NCT02275780Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2014
- Primary completion
- Sep 2016
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of doravirine in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Merck & Co. Primary endpoint: Percentage of Participants Achieving Plasma HIV-1 RNA <50 Copies/mL at 48 weeks. Started Dec 2014; status: completed.
02
Drugs
doravirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02275780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02275780.